The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma

Cancer

Volumn 88, Issue 10, 2000, Pages 2305-2318

  Vicini, Frank A ^a   Kestin, Larry L ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical failure; Prostate; Prostate specific antigen (PSA); Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0034658225     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2305::AID-CNCR15>3.0.CO;2-3     Document Type: Article

References (34)

1. Aref I, Eapen L, Agboola O, et al. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 1998;48:203-7'.
2. Critz FA, Levinson AK, Williams WH, Holladay CT, Griffin VD, Holladay DA. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol 1999;161:1199-205.
3. Crook JM, Choan E, Perry GA, Robertson S, Esche BA. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology 1998;51:566-72.
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:473-7.
5. Dawson NA. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 1998;16:3398-405.
6. Peschel RE. Prostate-specific antigen following radiation therapy [letter]. Int J Radiat Oncol Biol Phys 1996;36:749-51.
7. Sartor CI, Strawderman MH, Lin X, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-7.
8. Schellhammer P, Cockett A, Boccon-Gibod L, Gospodarowicz M, Krongrad A, Thompson IM, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology 1997;49(Suppl 4A):27-38.
9. Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU.. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996;47: 236-9.
10. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate cancer treated with external beam radiation therapy. Cancer 1999; 86:1557-66.
11. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:553-61.
12. Ennis RD, Malyszko BK, Heitjan DF, Rubin MA, O'Toole KM, Schiff PB.. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:511-7.
13. Pickles T, Duncan GG, Kim-Sing C, McKenzie MR, Morris WJ. PSA relapse definitions - the Vancouver Rules show superior predictive power [letter]. Int J Radiat Oncol Biol Phys 1999;43:699-700.
14. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996;36:565-71.
15. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
16. American Joint Committee on Cancer. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, et al., editors. AJCC cancer staging manual, 4th ed. Philadelphia: Lippincott-Raven, 1993:189-93.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
20. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-604.
21. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systemic biopsy and serum prostate specific antigen. Cancer 1997;79:328-36.
22. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostate specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993;27:125-7.
23. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 1998; 41:267-72.
24. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostate cancer: followup. J Urol 1993;149:519-22.
25. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
26. Russell KJ, Dunatov C, Hafermann MD, Griffeth JT, Polissar L, Pelton J, et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991;146: 1046-52.
27. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:293-306.
28. Zeitman AL, Shipley WU. Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 1993; 71:959-69.
29. Hanlon AL, Moore DF, Hanks GE. Modeling postradiation prostate specific antigen level kinetics. Cancer 1998;83: 130-4.
30. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997;44:213-21.
31. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Cancer 1993;72:832-42.
32. Willet CG, Zietman AL, Shipley WU, et al. The effect of pelvic radiation therapy on the production of prostatic specific antigen. J Urol 1994;151:1579-81.
33. Zeitman AL, Zehr EM, Shipley WU. Long-term effect of PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys 1999;43:715-8.
34. McLaughlin PW, Sandler HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy: how low can you go? [letter]. J Clin Oncol 1996;14:2889-92.